Search

Background The Orsiro is a hybrid stent which has passive (amorphous silicon carbide) and active (poly-L-lactic acid, PLLA) coatings. The first layer encapsulates the stent struts, promoting lower local inflammation, whereas the second layer releases sirolimus through a biodegradable matrix. This study's aim was to compare the results of percutaneous coronary interventions (PCI) with Orsiro and Xience™ V stents (everolimus-eluting stent) in daily clinical practice. Methods Observational study in which patients were divided into two groups: those who received only one or more Orsiro stents, and those who received only XienceTM V stents. Early and late outcomes were prospectively collected. Results Between September 2012 and March 2014, this study included 92 and 108 patients treated with Orsiro and Xience™ V stents, respectively. Clinical, angiographic, and procedure characteristics were mostly similar between groups. Rates of procedure success (98.9% vs. 95.4%; p = 0.22), in-hospital mortality (1.1% vs. 0%; p = 0.40) and stent thrombosis (0% vs. 0.9%, p = 0.30) did not differ between groups. Time of follow-up was 434 ± 111 and 477 ± 66 days (p = 0.23), respectively, and differences in mortality (0.9% vs. 0%, p = 0.30), stent thrombosis (0% vs. 0.9%; p = 0.30), or need for repeat revascularization of the target lesion (0% vs. 0.9%; p = 0.30) were not observed. Conclusions Orsiro and Xience™ V stents showed similar performance, with low rates of early and late clinical and angiographic events.

INTRODUÇÃO: Dados observacionais da década de 90 sugerem que pacientes com mais de 70 anos de idade evoluem com maior risco de eventos quando submetidos a intervenção coronariana percutânea (ICP). OBJETIVO: Avaliar os desfechos hospitalares em pacientes com idade superior a 70 anos submetidos a ICP na era contemporânea. MÉTODO: Entre janeiro de 2005 e junho de 2007, pacientes submetidos a ICP foram incluídos consecutivamente em um registro. Informações referentes a fatores de risco, indicação do exame, detalhes técnicos da ICP e desfechos intra-hospitalares foram prospectivamente coletadas. Os pacientes foram divididos em dois grupos: idade < ou > 70 anos. Para comparação, foram utilizados os testes t de Student e qui-quadrado, para variáveis contínuas e categóricas, respectivamente. Valores de p < 0,05 foram considerados diferença estatisticamente significante. RESULTADOS: Foram incluídos na análise 296 pacientes (186 com < 70 anos e 110 com > 70 anos). Não foi observada diferença em relação às características clínico-angiográficas entre os grupos e o sucesso angiográfico foi semelhante (96,6% vs. 97,1%; p = 0,91). Ocorreu tendência a maior mortalidade (1,81% vs. 0,53%; p = 0,06) e a maior incidência de acidente vascular encefálico (1,81% vs. 0%; p = 0,06) no grupo mais idoso. A incidência de cirurgia de urgência e de complicações vasculares não diferiu entre os grupos. Ocorreu maior incidência de nefropatia induzida pelo contraste no grupo > 70 anos (2,7% vs. 0%; p = 0,02). CONCLUSÃO: Pacientes com idade > 70 anos apresentaram incidência aumentada de nefropatia induzida pelo contraste e tendência a maior mortalidade e a maior ocorrência de acidente vascular encefálico. INTRODUCTION: Observational data from the 90's demonstrates that elderly population has an increased risk when treated by percutaneous coronary intervention (PCI). OBJECTIVE: To evaluate in-hospital outcomes in patients aged > 70 years old who underwent PCI in the current era. METHODS: In a single center, from January/2005 to June/2007, a total of 296 patients who underwent PCI were included in this analysis. The presence of risk factors, angiographic characteristics and in-hospital outcomes were recorded and compared among patients < 70-yo (n = 186) and > 70-yo (n = 110) in a dedicated database. For comparison purposes, unpaired t test and chi-square were used for continuous and dichotomous variables respectively. An alpha < 0.05 was considered significant. RESULTS: There was no difference between groups < 70-yo and > 70-yo regarding clinical presentation and the presence of risk factors for cardiovascular disease. Also, there was a homogenous distribution of treated vessels, angiographic pattern, coronary calcification and success rate (96.6% in > 70-yo group x 97.1% < 70-yo, p = 0.91). Regarding complications, there was an increased rate of contrast induced nephropathy in the older group (2.7% x 0%, p = 0.02) that required dialysis. Additionally, we observed a trend in higher mortality (1.81% x 0.53%, p = 0.06) and neurological compromise (1.81% x 0%, p = 0.06) in the elderly population. Vascular complication rates and urgent surgical revascularization were similar in both groups. CONCLUSION: Patients older and younger than 70-yo present similar clinical profile, angiographic characteristics and success rate. However, the incidence of contrast-induced nephropathy requiring dialysis, mortality and neurological compromise are higher in the older group.

Percutaneous coronary intervention (PCI) is a widely performed technique for coronary revascularization. Men and women seem to have different in-hospital outcomes, although results remain unclear. We assessed the gender impact on in-hospital outcomes in men and women undergoing PCI.In a single center, from 1998 to 2002, a total of 413 patients who underwent PCI were included in this analysis. From a dedicated database, the presence of risk factors, angiographic characteristics, left ventricular function and in-hospital outcomes were recorded and compared between men (n=244) and women (n=169). For comparison, unpaired t test and chi-square were used for continuous and dichotomous variables respectively. An alpha0.05 was considered significant.Women were older (65.3+/-10.39 x 60+/-10.68 years, p=0.001), presented better ejection fraction (67.01+/-12.28% x 64.26+/-14.31%, p=0.028) and higher prevalence of stable angina (63.90% x 45.90%, p0.001) than men. There were no differences related to family history for cardiovascular disease, hypertension, diabetes or hyperlipidemia; but there was an observed reduction in tobacco use (17.71% x 32.31%, p0.001) by women. Similar rates of in-hospital successful procedures (94.3% x 94.90%, p=0.93) and death (0.41%x1.18%, p=0.40) were observed in men and women, respectively. Neither vascular complications nor stroke occurred. There was a higher incidence of urgent surgical myocardial revascularization (1.77%x0%, p=0.036) and a trend in the combined outcome of death/surgical myocardial revascularization (2.69% x 0.41%, p=0.06) in the women's group.Women present a higher incidence of urgent surgical myocardial revascularization following percutaneous coronary intervention when compared to men.

ResumoIntroduçãoO stent Orsiro é um stent híbrido que possui revestimentos passivo (carbeto de silício amorfo) e ativo (ácido poli‐L‐lático, PLLA). O primeiro encapsula as hastes do stent, promovendo menor inflamação local, e o segundo libera o sirolimus por meio de matriz biodegradável. Nosso objetivo foi comparar os resultados das intervenções coronárias percutâneas (ICP) dos stents Orsiro e Xience® V (eluidor de everolimus) na prática clínica diária.MétodosEstudo observacional em que os pacientes foram alocados em dois grupos: os que receberam exclusivamente um ou mais stents Orsiro e os que receberam exclusivamente stents Xience® V. Desfechos iniciais e tardios foram prospectivamente coletados.ResultadosEntre setembro de 2012 e março de 2014, incluímos 92 e 108 pacientes tratados com stent Orsiro e Xience® V, respectivamente. Características clínicas, angiográficas e do procedimento foram, em sua maioria, semelhantes entre os grupos. As taxas de sucesso do procedimento (98,9% vs. 95,4%; p = 0,22), mortalidade (1,1% vs. 0%; p = 0,40) e trombose do stent (0% vs. 0,9%; p = 0,30) hospitalares não diferiram entre os grupos. O tempo de seguimento foi de 434 ± 111 e 477 ± 66 dias (p = 0,23), respectivamente, não sendo observadas diferenças na mortalidade (0,9% vs. 0%; p = 0,30), trombose do stent (0% vs. 0,9%; p = 0,30) e nem na necessidade de revascularização da lesão alvo (0% vs. 0,9%; p = 0,30).ConclusõesOs stents Orsiro e Xience® V apresentaram desempenho semelhante, com baixas taxas de eventos clínicos e angiográficos iniciais e tardios.AbstractBackgroundThe Orsiro is a hybrid stent which has passive (amorphous silicon carbide) and active (poly‐L‐lactic acid, PLLA) coatings. The first layer encapsulates the stent struts, promoting lower local inflammation, whereas the second layer releases sirolimus through a biodegradable matrix. This study's aim was to compare the results of percutaneous coronary interventions (PCI) with Orsiro and Xience™ V stents (everolimus‐eluting stent) in daily clinical practice.MethodsObservational study in which patients were divided into two groups: those who received only one or more Orsiro stents, and those who received only XienceTM V stents. Early and late outcomes were prospectively collected.ResultsBetween September 2012 and March 2014, this study included 92 and 108 patients treated with Orsiro and Xience™ V stents, respectively. Clinical, angiographic, and procedure characteristics were mostly similar between groups. Rates of procedure success (98.9% vs. 95.4%; p = 0.22), in‐hospital mortality (1.1% vs. 0%; p = 0.40) and stent thrombosis (0% vs. 0.9%, p = 0.30) did not differ between groups. Time of follow‐up was 434 ± 111 and 477 ± 66 days (p = 0.23), respectively, and differences in mortality (0.9% vs. 0%, p = 0.30), stent thrombosis (0% vs. 0.9%; p = 0.30), or need for repeat revascularization of the target lesion (0% vs. 0.9%; p = 0.30) were not observed.ConclusionsOrsiro and Xience™ V stents showed similar performance, with low rates of early and late clinical and angiographic events.